HIV mutation literature information.


  Prevention of mother-to-child HIV-1 transmission in Burkina Faso: evaluation of vertical transmission by PCR, molecular characterization of subtypes and determination of antiretroviral drugs resistance.
 PMID: 25630709       2015       Global health action
Table: E138A


  In vitro activity of dolutegravir against wild-type and integrase inhibitor-resistant HIV-2.
 PMID: 25808007       2015       Retrovirology
Result: In addition, the roles of novel INSTI-associated changes (i.e, H51Y, G118R, F121Y, E138A/K, and R263K) remain to be determined in HIV-2, and the level of dolutegravir resistance in vitro that correlates with virologic failure in HIV-2-infected patients is unknown.


  Geographic and temporal trends in the molecular epidemiology and genetic mechanisms of transmitted HIV-1 drug resistance: an individual-patient- and sequence-level meta-analysis.
 PMID: 25849352       2015       PLoS medicine
Result: However, among the 48,722 samples without NNRTI SDRMs, 5.6% (644 of 11,536) of samples in SSA, 1.6% (104 of 6,522) in SSEA, and 2.6% (655 of 25,035) in the pooled upper-income countries were predicted to have low-level rilpivirine resistance as a result of the polymorphic mutation E138A, which occurs in up to 6% of subtype A and C viruses.


  [Resistance profile and genetic barrier of dolutegravir].
 PMID: 25858608       2015       Enfermedades infecciosas y microbiologia clinica
Abstract: Dolutegravir displays in vitro activity against mutant HIV-1 harboring any isolated resistance mutations selected during failures to raltegravir or elvitegravir (Y143C/H/, N155H, Q148H/K/R, E92G/Q, T66A/I/K, T97A, E138A/K, G140A/S).


  HIV-1 diversity in an antiretroviral treatment naive cohort from Bushbuckridge, Mpumalanga Province, South Africa.
 PMID: 25889106       2015       Virology journal
Abstract: Antiretroviral drug resistance mutations K103N and E138A were also detected, indicating possible transmission of anti-retroviral drug resistance mutations.
Result: The NNRTI mutation, E138A, detected on the 0143A sequence is a polymorphism that may contribute to reduced etravirine (ETR) and rilpivirine (RPV) susceptibility in combination with other NNRTI-resistance mutations.
Table: E138A


  Influence of Drug Resistance Mutations on the Activity of HIV-1 Subtypes A and B Integrases: a Comparative Study.
 PMID: 25927004       2015       Acta naturae
Introduction: In most cases, this mutation occurs in combination with secondary mutations, most frequently G140S/A and E138K/A.
Introduction: Secondary and tertiary mutations (G140A/C/S, L74I and E138A/K/T) further enhance the resistance.


  A post-partum single-dose TDF/FTC tail does not prevent the selection of NNRTI resistance in women receiving pre-partum ZDV and intrapartum single-dose nevirapine to prevent mother-to- child HIV-1 transmission.
 PMID: 25940687       2015       Journal of medical virology
Result: V90I and E138A were detected in each of two patients.


  [Primary HIV resistance in Buenos Aires metropolitan area].
 PMID: 26117607       2015       Medicina
Abstract: Mutations conferring low-level resistance to rilpivirine were found in 3 (3.3%) patients; such mutations were E138A and E138G.


  Resistance against Integrase Strand Transfer Inhibitors and Relevance to HIV Persistence.
 PMID: 26198244       2015       Viruses
Introduction: One of them possessed an integrase V151V/I mixed population that was not phenotypically resistant against DTG while the other possessed substitutions at positions T97A and E138T/A and was shown to have high levels of resistance against DTG.
Table: E138T/A


  Expansion of the CRF19_cpx Variant in Spain.
 PMID: 26209397       2015       Journal of clinical virology
Abstract: Resistance mutations in the RT region were found in all sequences from group A (V139D) and in two sequences from group B (E138A).



Browser Board

 Co-occurred Entities




   Filtrator